Adenomyosis is a condition where endometrial tissue — the tissue that normally lines the inside of the uterus — grows into the muscular wall (myometrium) of the uterus. This displaced tissue continues to behave as it normally would during each menstrual cycle: thickening, breaking down, and bleeding. But because it is trapped within the muscle, the blood and tissue have no way to exit, causing the uterus to enlarge, become tender, and produce increasingly severe symptoms.
If this description sounds similar to endometriosis, that is because the two conditions share a common mechanism — endometrial tissue growing where it should not. The critical difference is location. In endometriosis, the tissue grows outside the uterus (on ovaries, fallopian tubes, bowel, bladder, and pelvic surfaces). In adenomyosis, the tissue burrows inward into the uterine muscle itself. The two conditions frequently coexist — an estimated 20% to 80% of women with adenomyosis also have endometriosis — but they are distinct conditions with different diagnostic approaches and somewhat different treatment strategies.
Why Adenomyosis Goes Undiagnosed
Adenomyosis has historically been considered a condition of older, multiparous (having given birth multiple times) women, often diagnosed incidentally during hysterectomy. This outdated perception delayed diagnosis for decades because clinicians simply were not looking for it in younger women or considering it in the differential diagnosis for pelvic pain.
Modern imaging has revealed that adenomyosis is far more common and affects a much broader population than previously recognized. MRI studies of unselected populations suggest prevalence rates of 20% to 35% among women of reproductive age. The condition affects women of all ages, parities, and backgrounds — though prevalence does increase with age and may be higher in women who have had uterine surgery.
The average time from symptom onset to diagnosis ranges from five to ten years in published studies. Contributing factors to this diagnostic delay include symptom overlap with other common conditions (endometriosis, fibroids, primary dysmenorrhea), normalization of menstrual pain by both women and their physicians, reliance on transvaginal ultrasound performed by operators without specific adenomyosis training (standard ultrasound frequently misses adenomyosis), and the historical belief that definitive diagnosis required histological examination of a hysterectomy specimen.
Recognizing the Symptoms
Adenomyosis produces a characteristic cluster of symptoms, though severity varies enormously between individuals. Some women with adenomyosis visible on imaging are completely asymptomatic. Others experience disabling symptoms that fundamentally limit their daily functioning.
Heavy menstrual bleeding (menorrhagia) is the most common symptom, affecting approximately 50% to 70% of symptomatic women. The bleeding is characteristically heavy from the first day, often with passage of large clots, and may progressively worsen over years as the condition advances. The enlarged, congested uterine muscle contracts less effectively during menstruation, impairing the normal hemostatic (bleeding-control) mechanisms. Many women with adenomyosis develop iron deficiency anemia from chronic heavy blood loss.
Severe menstrual cramps (dysmenorrhea) affect 15% to 30% of women with adenomyosis and are often described as deep, aching, cramping pain that begins before menstruation and continues throughout the period. The pain typically worsens over years and may become increasingly resistant to standard over-the-counter pain medications. The mechanism involves both the trapped endometrial tissue creating localized inflammation and the enlarged uterus contracting more forcefully to expel menstrual blood.
Chronic pelvic pain unrelated to menstruation occurs in some women, particularly those with more extensive disease. This pain may be constant or intermittent and can include a sensation of pelvic heaviness or pressure.
Pain during intercourse (dyspareunia) — particularly deep dyspareunia that worsens during menstruation — affects a significant minority of women with adenomyosis. The enlarged, tender uterus is more sensitive to the mechanical displacement that occurs during penetrative intercourse.
Bloating and pelvic pressure result from uterine enlargement. In advanced adenomyosis, the uterus can enlarge to the size of a 12-week pregnancy or larger, causing visible abdominal distension and pressure on the bladder (frequent urination) and rectum (constipation, pressure sensation).
Fertility impact is an area of active research. Adenomyosis has been associated with reduced implantation rates, increased miscarriage rates, and pregnancy complications including preterm delivery. The American Society for Reproductive Medicine recognizes adenomyosis as a potential contributor to infertility, particularly in women undergoing IVF where implantation failure despite good-quality embryos may be related to adenomyotic changes in the uterine wall.
How Adenomyosis Differs From Endometriosis
While adenomyosis and endometriosis share the fundamental problem of ectopic endometrial tissue, their clinical characteristics differ in important ways.
Pain patterns differ. Endometriosis pain is often most severe during ovulation and pre-menstrually, with pain that may involve the bowel, bladder, and other pelvic structures depending on implant location. Adenomyosis pain is most characteristically associated with menstruation itself — heavy, cramping menstrual pain — though chronic pain occurs in both conditions.
Bleeding patterns differ. Endometriosis does not typically cause heavy menstrual bleeding (it may cause intermenstrual spotting or irregular bleeding). Adenomyosis characteristically produces progressively heavier menstrual bleeding as the condition advances.
Physical examination findings differ. Endometriosis may produce a normal exam or tenderness on pelvic exam, but the uterus is typically normal size. Adenomyosis causes a diffusely enlarged, globular, tender uterus that an experienced examiner can often detect on bimanual examination.
Imaging findings differ. Endometriosis is poorly visualized on standard imaging (laparoscopy remains the gold standard for diagnosis). Adenomyosis can be diagnosed non-invasively through MRI and, increasingly, through expert transvaginal ultrasound.
Treatment approaches overlap but differ. Both conditions respond to hormonal suppression, but adenomyosis-specific treatments (such as uterine artery embolization) target the uterine pathology directly, while endometriosis treatment often requires surgical excision of implants.
Diagnosis: The Imaging Revolution
The diagnosis of adenomyosis has been transformed by advances in imaging, though the quality of diagnosis depends heavily on operator expertise.
Transvaginal ultrasound (TVUS) performed by a sonographer or physician trained in adenomyosis detection can diagnose the condition with sensitivity and specificity approaching 80% to 90%. Key ultrasound features include asymmetric myometrial thickening, heterogeneous myometrial echotexture with myometrial cysts, poor definition of the endometrial-myometrial junction (junctional zone), and globular uterine enlargement. The critical caveat is that standard pelvic ultrasound — the type performed in most radiology departments — frequently misses adenomyosis because operators are not specifically trained to look for these features.
MRI is considered the gold standard for non-invasive adenomyosis diagnosis. It clearly demonstrates junctional zone thickening (the hallmark MRI finding — a junctional zone exceeding 12 mm is highly suggestive), myometrial cysts, and the extent and distribution of disease within the uterine wall. MRI is particularly valuable for surgical planning and for distinguishing adenomyosis from fibroids, which can have overlapping ultrasound appearances.
If your imaging reports do not mention the junctional zone or specifically address adenomyosis, the examination may not have adequately evaluated for the condition. Requesting imaging by a specialist experienced in adenomyosis — or specifically requesting MRI with attention to the junctional zone — improves diagnostic accuracy.
Treatment Options
Treatment selection depends on symptom severity, desire for future fertility, age, and patient preferences.
Medical Management
Hormonal therapies that suppress or modify the menstrual cycle form the first line of treatment. The levonorgestrel IUD (Mirena) is one of the most effective medical treatments for adenomyosis-related heavy bleeding, reducing menstrual blood loss by 70% to 90% in most women. It delivers progesterone directly to the uterine lining and muscle, thinning the endometrium and reducing the activity of adenomyotic implants. Many women achieve near-complete resolution of bleeding, and some achieve amenorrhea (no periods).
Combined oral contraceptives taken continuously (skipping the placebo week) suppress menstruation and reduce adenomyosis symptoms. Progestin-only pills (norethindrone, dienogest) provide an alternative for women who cannot take estrogen.
GnRH agonists (like leuprolide) create temporary medical menopause, dramatically shrinking adenomyotic tissue and stopping bleeding. Side effects limit use to three to six months typically, but they may be used pre-operatively to shrink the uterus or as a bridge to menopause in older women.
NSAIDs (ibuprofen, naproxen) do not treat the underlying condition but can reduce menstrual pain and modestly decrease bleeding volume.
Tranexamic acid reduces menstrual blood loss by 30% to 50% without affecting the menstrual cycle and can be used alongside hormonal treatments.
Procedural and Surgical Options
Uterine artery embolization (UAE), the same procedure used for fibroids, has shown effectiveness for adenomyosis. By reducing blood flow to the adenomyotic tissue, UAE produces symptom improvement in 65% to 85% of women. However, the evidence base for UAE in adenomyosis is smaller than for fibroids, and long-term data is limited.
Adenomyomectomy — surgical excision of adenomyotic tissue while preserving the uterus — is technically challenging because adenomyosis does not have clear boundaries like fibroids. It is performed by select surgeons at specialized centers and may be an option for women desiring fertility who have localized (focal) adenomyosis.
High-intensity focused ultrasound (HIFU) is an emerging non-invasive treatment that uses focused ultrasound energy to destroy adenomyotic tissue without incisions. Early results are promising, but the technology is not widely available and long-term outcomes data is limited.
Hysterectomy remains the only definitive treatment that eliminates adenomyosis completely. For women who have completed childbearing and whose symptoms are not adequately controlled by other treatments, hysterectomy provides permanent resolution. Ovary preservation is standard practice unless there are independent indications for removal, allowing natural hormonal function to continue.
The Path Forward
If you recognize your symptoms in this guide, the most important next step is seeking evaluation by a gynecologist experienced in adenomyosis. Request imaging specifically evaluated for adenomyosis features (MRI or expert TVUS). Armed with an accurate diagnosis, you can work with your provider to develop a treatment plan that addresses your symptoms while respecting your reproductive goals.
Adenomyosis is not something you need to endure silently. It is a real, diagnosable condition with multiple effective treatment options. The years-long diagnostic delays that characterize this condition are not inevitable — they are the result of insufficient awareness among both women and clinicians. By understanding what adenomyosis is and how it presents, you can advocate effectively for appropriate evaluation and treatment.
Sources and Further Reading
Health and Beyond uses reputable medical and scientific sources where possible. These links support or expand on the topics discussed above.
